Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Disease Progression × Bevacizumab × Clear all

Phase

Phase 3 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Colorectal Neoplasms 74 Ovarian Neoplasms 28 Carcinoma, Non-Small-Cell Lung 24 Breast Neoplasms 24 Colonic Neoplasms 20 Rectal Neoplasms 18 Neoplasms 16 Fallopian Tube Neoplasms 16 Neoplasm Metastasis 11 Carcinoma, Hepatocellular 11 Glioblastoma 10 Carcinoma, Renal Cell 7 Brain Neoplasms 7 Parkinson Disease 4, Autosomal Dominant Lewy Body 6 Lung Neoplasms 6 Uterine Cervical Neoplasms 5 Intestinal Neoplasms 5 Gastrointestinal Neoplasms 5 Digestive System Neoplasms 5 Brenner Tumor 5 Recurrence 4 Glioma 4 Rectal Diseases 3 Peritoneal Neoplasms 3 Liver Neoplasms 3 Intestinal Diseases 3 Gastrointestinal Diseases 3 Digestive System Diseases 3 Colonic Diseases 3 Carcinoma, Ovarian Epithelial 3

Interventions

Lenalidomide 3 capivasertib 2 Bortezomib 2 tivozanib 1 Zoledronic Acid 1 Vitamin D 1 Temozolomide 1 Radiotherapy 1 Nivolumab 1 Fulvestrant 1 Etoposide 1 Dexamethasone 1 Cisplatin 1 Carboplatin 1 Calcium Dobesilate 1 Calcium 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02761070 2023-03-08

RE-GEND

Kyorin University

Phase 3 Unknown

Glioblastoma, Recurrence, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon ⚡